Advancing Multiple mRNA Clinical Studies

Across our internally developed and partnered mRNA programs, we are simultaneously advancing mRNA drugs for many diseases into and through clinical studies. Our Early Development Engine enables this with a combination of internal and external capabilities around process development, conduct of Good Laboratory Practice (GLP) (IND-enabling) toxicology studies, global regulatory interactions and clinical study preparation and execution. The Early Development Engine is structured to deliver many high quality mRNA drugs to human proof of concept (PoC) data.

Our Approach to Early Drug Development

Our early development process is designed to deliver the highest quality mRNA drugs from development candidate (DC) nomination to human proof-of-concept (PoC) data. This is how we approach the process.

Download facts and figures on our new Norwood manufacturing site.

Early Development Engine Components

Learn about the various components of our integrated Early Development Engine.


An example of the speed enabled by our Research Engine and Early Development Engine: Moderna was able to move our Zika mRNA vaccine (mRNA-1325) from idea to IND filing in 10 months and from idea to clinical study in 12 months.